IBD ETF

A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.

Meta stock and Nvidia peer Broadcom are among among five S&P 500 stocks on IBD Leaderboard that are near buy points. The post Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points appeared first on Investor's Business Daily.

Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033.

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and  Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

A smart beta exchange traded fund, the Inspire Corporate Bond ETF (IBD) debuted on 07/10/2017, and offers broad exposure to the Investment Grade Corporate Bond ETFs category of the market.

Eli Lilly and Co (NYSE:LLY) has struck a deal to acquire Morphic Holding Inc (NASDAQ:MORF), a maker of inflammatory bowel disease (IBD) drugs, for approximately $3.2 billion. On a per-share basis the deal is priced at $57, to be paid in cash.

As I've noted in a few past columns, “Investor's Business Daily's IBD 50 is ‘a weekly, rules-based, computer-generated stock index.'” Moreover, the stocks on the list tend to be fundamentally strong and have top-notch growth outlooks.

IBD's Alexis Garcia and Ed Carson give a preview of important upcoming earnings reports from Nvidia, PDD, Toll Brothers, and other companies. Are you new to trading?

The Inspire Corporate Bond ETF (IBD) made its debut on 07/10/2017, and is a smart beta exchange traded fund that provides broad exposure to the Investment Grade Corporate Bond ETFs category of the market.